AT HEART FAILURE 2017
PARIS (FRONTLINE MEDICAL NEWS) – Heart failure patients who received guideline-directed pharmacotherapy therapy, at dosages that approached guideline-directed levels, had roughly half the 6-month mortality as did similar patients who did not receive this level of treatment in a real-world, observational study with more than 6,000 patients.
Adherence to pharmacologic treatment guidelines for patients with heart failure with reduced ejection fraction (HFrEF) “was strongly associated with clinical outcomes during 6-month follow-up,” Michel Komajda, MD , said at a meeting held by the Heart Failure Association of the European Society of Cardiology. The findings highlight the importance of closely following guideline recommendations in routine practice.
Dr. Komajda’s analysis included six different outcome measures. The most striking benefits were reductions in all-cause mortality, death from cardiovascular causes, and heart failure death. Each of these three 6-month endpoints were roughly twice as high in HFrEF patients who either had poor or moderate adherence to guideline treatments, compared with patients with good adherence, in multivariate analyses that controlled for baseline demographic and clinical differences. Good treatment adherence also aligned with reductions in heart failure hospitalizations and cardiovascular disease hospitalizations.
The analysis used data collected in the QUALIFY (Quality of Adherence to Guideline Recommendations for Life-Saving Treatment in Heart Failure: an International Survey) registry, which enrolled 7,127 HFrEF patients during September 2013–December 2014 at 547 centers in 36 countries, mostly in Europe, Asia, and Africa but also in Canada, Ecuador, and Australia. All enrolled patients had to have been hospitalized for worsening heart failure at least once during the 1-15 months before they entered QUALIFY.
Dr. Komajda and his associates assessed each enrolled patient at baseline by their treatment with each of four guideline-recommended drug classes: an ACE inhibitor or angiotensin receptor blocker; a beta-blocker; an aldosterone receptor antagonist (ARA) if the patient’s functional status was rated as New York Heart Association class II, III, or IV; and ivabradine (Corlanor) if the patient was in NYHA class II, III, or IV, in sinus rhythm, had a heart rate of at least 70 beats per minute, and if the patient was in a country where ivabradine was available. Because patient enrollment occurred in 2013 and 2014, the study couldn’t include the new formulation of sacubitril plus valsartan (Entresto) in its analysis.
For each eligible drug class a patient received 1 point if their daily prescribed dosage was at least 50% of the recommended dosage (or 100% for an ARA), 0.5 points if the patient received the recommended drug but at a lower dosage, and no points if the drug wasn’t given. A patient also received 1 point if they were appropriately not given a drug because of a documented contraindication or intolerance. The researchers then calculated each patient’s “adherence score” by dividing their point total by the potentially maximum number of points that each patient could have received (a number that ranged from 2 to 4). They defined a score of 1 (which meant the patients received at least half the recommended dosage of all recommended drugs) as good adherence, a score of 0.51-0.99 as moderate adherence, and a score of 0.5 or less as poor adherence.
Six-month follow-up results were available for 6,669 patients. The baseline adherence scores for these patients included 1,543 (23%) with good adherence, 3631 (54%) with moderate adherence, and 1,495 (22%) with poor adherence (percentages total 99% because of rounding), reported Dr. Komajda, a professor of cardiology at the Pitié Salpêtrière University Hospital, Paris. Patients in the three adherence subgroups generally showed similar baseline demographic and clinical patterns. The patients averaged about 63 years of age, about three-quarters were men, their average duration of HFrEF was about 4 years, and 30% had a history of at least two prior heart failure hospitalizations within the preceding 15 months. About 80% of patients were either in New York Heart Association functional class II or III.
Because patient enrollment occurred during 2013 and 2014, the benchmark heart failure treatment guidelines were those issued by the European Society of Cardiology in 2012 (Eur Heart J. 2012 July; 33:1787-1847 ).
Concurrently with Dr. Komajda’s report at the meeting the results appeared in an article online (Eur J Heart Failure. 2017. doi: 10.1002/ejhf.887 ).
QUANTIFY was sponsored by Servier. Dr. Komajda has received honoraria from Servier and from Amgen, AstraZeneca, Bristol-Myers Squibb, Menarini, MSD, Novartis, Novo Nordisk, and Sanofi.
On Twitter @mitchelzoler